当前位置: 首页 >> 检索结果
421. Teprasiran, a Small Interfering RNA, for the Prevention of Acute Kidney Injury in High-Risk Patients Undergoing Cardiac Surgery: A Randomized Clinical Study.
作者: Matthias Thielmann.;David Corteville.;Gabor Szabo.;Madhav Swaminathan.;Andre Lamy.;Lukas J Lehner.;Craig D Brown.;Nicolas Noiseux.;Mohamed G Atta.;Elizabeth C Squiers.;Shai Erlich.;Daniel Rothenstein.;Bruce Molitoris.;C David Mazer.
来源: Circulation. 2021年144卷14期1133-1144页
Acute kidney injury (AKI) affects up to 30% of patients undergoing cardiac surgery, leading to increased in-hospital and long-term morbidity and mortality. Teprasiran is a novel small interfering RNA that temporarily inhibits p53-mediated cell death that underlies AKI.
422. Cryoballoon Versus High-Power, Short-Duration Radiofrequency Ablation for Pulmonary Vein Isolation in Patients With Paroxysmal Atrial Fibrillation: A Single-Center, Prospective, Randomized Study.
作者: Hui-Nam Pak.;Je-Wook Park.;Song-Yi Yang.;Tae-Hoon Kim.;Jae-Sun Uhm.;Boyoung Joung.;Moon-Hyoung Lee.;Hee Tae Yu.
来源: Circ Arrhythm Electrophysiol. 2021年14卷9期e010040页
[Figure: see text].
423. Predictive Accuracy of a Clinical and Genetic Risk Model for Atrial Fibrillation.
作者: Shaan Khurshid.;Nina Mars.;Christopher M Haggerty.;Qiuxi Huang.;Lu-Chen Weng.;Dustin N Hartzel.; .;Kathryn L Lunetta.;Jeffrey M Ashburner.;Christopher D Anderson.;Emelia J Benjamin.;Veikko Salomaa.;Patrick T Ellinor.;Brandon K Fornwalt.;Samuli Ripatti.;Ludovic Trinquart.;Steven A Lubitz.
来源: Circ Genom Precis Med. 2021年14卷5期e003355页
Atrial fibrillation (AF) risk estimation using clinical factors with or without genetic information may identify AF screening candidates more accurately than the guideline-based age threshold of ≥65 years.
424. Genotype-Phenotype Correlation of SCN5A Genotype in Patients With Brugada Syndrome and Arrhythmic Events: Insights From the SABRUS in 392 Probands.
作者: Anat Milman.;Elijah R Behr.;Belinda Gray.;David C Johnson.;Antoine Andorin.;Aviram Hochstadt.;Jean-Baptiste Gourraud.;Shingo Maeda.;Yoshihide Takahashi.;Jimmy Jm Juang.;Sung-Hwan Kim.;Tsukasa Kamakura.;Takeshi Aiba.;Pieter G Postema.;Yuka Mizusawa.;Isabelle Denjoy.;Carla Giustetto.;Giulio Conte.;Zhengrong Huang.;Georgia Sarquella-Brugada.;Andrea Mazzanti.;Camilla H Jespersen.;Elena Arbelo.;Ramon Brugada.;Leonardo Calo.;Domenico Corrado.;Ruben Casado-Arroyo.;Giuseppe Allocca.;Masahiko Takagi.;Pietro Delise.;Josep Brugada.;Jacob Tfelt-Hansen.;Silvia G Priori.;Christian Veltmann.;Gan-Xin Yan.;Pedro Brugada.;Fiorenzo Gaita.;Antoine Leenhardt.;Arthur A M Wilde.;Kengo F Kusano.;Gi-Byoung Nam.;Kenzo Hirao.;Vincent Probst.;Bernard Belhassen.
来源: Circ Genom Precis Med. 2021年14卷5期e003222页
Brugada syndrome (BrS) is associated with mutations in the cardiac sodium channel gene, SCN5A. However, genetic studies of patients with BrS with arrhythmic events have been limited. We sought to compare various clinical, ECG, and electrophysiological parameters according to SCN5A genotype in a large cohort of BrS probands with first arrhythmic event.
425. Contribution of Noncanonical Splice Variants to TTN Truncating Variant Cardiomyopathy.
作者: Parth N Patel.;Kaoru Ito.;Jon A L Willcox.;Alireza Haghighi.;Min Young Jang.;Joshua M Gorham.;Steven R DePalma.;Lien Lam.;Barbara McDonough.;Renee Johnson.;Neal K Lakdawala.;Amy Roberts.;Paul J R Barton.;Stuart A Cook.;Diane Fatkin.;Christine E Seidman.;J G Seidman.
来源: Circ Genom Precis Med. 2021年14卷5期e003389页
Heterozygous TTN truncating variants cause 10% to 20% of idiopathic dilated cardiomyopathy (DCM). Although variants which disrupt canonical splice signals (ie, invariant dinucleotide of the splice donor site, invariant dinucleotide of the splice acceptor site) at exon-intron junctions are readily recognized as TTN truncating variants, the effects of other nearby sequence variations on splicing and their contribution to disease is uncertain.
426. Presence of the V122I Variant of Hereditary Transthyretin-Mediated Amyloidosis Among Self-Reported White Individuals in a Sponsored Genetic Testing Program.
作者: Barry H Trachtenberg.;Sachin K Shah.;Robert L Nussbaum.;Sara L Bristow.;Ruthvik Malladi.;Matteo Vatta.
来源: Circ Genom Precis Med. 2021年14卷5期e003466页 427. Utility of Genetically Predicted Lp(a) (Lipoprotein [a]) and ApoB Levels for Cardiovascular Risk Assessment.
作者: Haoyu Wu.;Jian'an Luan.;Vincenzo Forgetta.;James C Engert.;George Thanassoulis.;Vincent Mooser.;Nicholas J Wareham.;Claudia Langenberg.;J Brent Richards.
来源: Circ Genom Precis Med. 2021年14卷5期e003312页
Current lipid guidelines suggest measurement of Lp(a) (lipoprotein[a]) and ApoB (apolipoprotein B) for atherosclerotic cardiovascular disease risk assessment. Polygenic risk scores (PRSs) for Lp(a) and ApoB may identify individuals unlikely to have elevated Lp(a) or ApoB and thus reduce such suggested testing.
428. Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial.
作者: Dhanunjaya Lakkireddy.;David Thaler.;Christopher R Ellis.;Vijendra Swarup.;Lars Sondergaard.;John Carroll.;Michael R Gold.;James Hermiller.;Hans-Christoph Diener.;Boris Schmidt.;Lee MacDonald.;Moussa Mansour.;Brijeshwar Maini.;Laura O'Brien.;Stephan Windecker.
来源: Circulation. 2021年144卷19期1543-1552页
Percutaneous closure of the left atrial appendage (LAA) is an alternative to chronic oral anticoagulation to reduce stroke risk in patients with nonvalvular atrial fibrillation. The Amulet IDE trial (Amplatzer Amulet Left Atrial Appendage Occluder IDE Trial) was designed to evaluate the safety and effectiveness of the dual-seal mechanism of the Amulet LAA occluder compared with the Watchman device.
429. Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.
作者: Renato D Lopes.;Celestia S Higano.;Susan F Slovin.;Adam J Nelson.;Robert Bigelow.;Per S Sørensen.;Chiara Melloni.;Shaun G Goodman.;Christopher P Evans.;Jan Nilsson.;Deepak L Bhatt.;Noel W Clarke.;Tine K Olesen.;Belinda T Doyle-Olsen.;Henriette Kristensen.;Lauren Arney.;Matthew T Roe.;John H Alexander.; .
来源: Circulation. 2021年144卷16期1295-1307页
The relative cardiovascular safety of gonadotropin-releasing hormone (GnRH) antagonists compared with GnRH agonists in men with prostate cancer and known atherosclerotic cardiovascular disease remains controversial.
430. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial.
作者: Milton Packer.;Javed Butler.;Faiez Zannad.;Gerasimos Filippatos.;Joao Pedro Ferreira.;Stuart J Pocock.;Peter Carson.;Inder Anand.;Wolfram Doehner.;Markus Haass.;Michel Komajda.;Alan Miller.;Steen Pehrson.;John R Teerlink.;Sven Schnaidt.;Cordula Zeller.;Janet M Schnee.;Stefan D Anker.
来源: Circulation. 2021年144卷16期1284-1294页
Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction, but additional data are needed about its effect on inpatient and outpatient heart failure events.
431. Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.
作者: Ole Fröbert.;Matthias Götberg.;David Erlinge.;Zubair Akhtar.;Evald H Christiansen.;Chandini R MacIntyre.;Keith G Oldroyd.;Zuzana Motovska.;Andrejs Erglis.;Rasmus Moer.;Ota Hlinomaz.;Lars Jakobsen.;Thomas Engstrøm.;Lisette O Jensen.;Christian O Fallesen.;Svend E Jensen.;Oskar Angerås.;Fredrik Calais.;Amra Kåregren.;Jörg Lauermann.;Arash Mokhtari.;Johan Nilsson.;Jonas Persson.;Per Stalby.;Abu K M M Islam.;Afzalur Rahman.;Fazila Malik.;Sohel Choudhury.;Timothy Collier.;Stuart J Pocock.;John Pernow.
来源: Circulation. 2021年144卷18期1476-1484页
Observational and small, randomized studies suggest that influenza vaccine may reduce future cardiovascular events in patients with cardiovascular disease.
432. Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial.
作者: Pieter C Smits.;Enrico Frigoli.;Jan Tijssen.;Peter Jüni.;Pascal Vranckx.;Yukio Ozaki.;Marie-Claude Morice.;Bernard Chevalier.;Yoshinobu Onuma.;Stephan Windecker.;Pim A L Tonino.;Marco Roffi.;Maciej Lesiak.;Felix Mahfoud.;Jozef Bartunek.;David Hildick-Smith.;Antonio Colombo.;Goran Stankovic.;Andrés Iñiguez.;Carl Schultz.;Ran Kornowski.;Paul J L Ong.;Mirvat Alasnag.;Alfredo E Rodriguez.;Aris Moschovitis.;Peep Laanmets.;Dik Heg.;Marco Valgimigli.; .
来源: Circulation. 2021年144卷15期1196-1211页
The optimal duration of antiplatelet therapy (APT) in patients at high bleeding risk with or without oral anticoagulation (OAC) after coronary stenting remains unclear.
433. Effects of Walnut Consumption for 2 Years on Lipoprotein Subclasses Among Healthy Elders: Findings From the WAHA Randomized Controlled Trial.
作者: Sujatha Rajaram.;Montserrat Cofán.;Aleix Sala-Vila.;Ella Haddad.;Mercè Serra-Mir.;Edward Bitok.;Irene Roth.;Tania M Freitas-Simoes.;Amandeep Kaur.;Cinta Valls-Pedret.;Mónica Doménech.;Keiji Oda.;Dolores Corella.;Joan Sabaté.;Emilio Ros.
来源: Circulation. 2021年144卷13期1083-1085页 434. Compared Outcomes of ST-Segment-Elevation Myocardial Infarction Patients With Multivessel Disease Treated With Primary Percutaneous Coronary Intervention and Preserved Fractional Flow Reserve of Nonculprit Lesions Treated Conservatively and of Those With Low Fractional Flow Reserve Managed Invasively: Insights From the FLOWER-MI Trial.
作者: Pierre Denormandie.;Tabassome Simon.;Guillaume Cayla.;Philippe Gabriel Steg.;Gilles Montalescot.;Isabelle Durand-Zaleski.;Alicia le Bras.;Hervé le Breton.;Yann Valy.;François Schiele.;Thomas Cuisset.;Gérald Vanzetto.;Sébastien Levesque.;Pascal Goube.;Olivier Nallet.;Denis Angoulvant.;François Roubille.;Anaïs Charles Nelson.;Gilles Chatellier.;Nicolas Danchin.;Etienne Puymirat.
来源: Circ Cardiovasc Interv. 2021年14卷11期e011314页
In patients with ST-segment-elevation myocardial infarction and multivessel disease, percutaneous coronary intervention (PCI) for nonculprit lesions guided by fractional flow reserve (FFR) is superior to treatment of the culprit lesion alone. Whether deferring nonculprit PCI is safe in this specific context is questionable. We aimed to assess clinical outcomes at 1 year in ST-segment-elevation myocardial infarction patients with multivessel coronary artery disease and an FFR-guided strategy for nonculprit lesions, according to whether or not ≥1 PCI was performed.
435. Catheter-Based Adrenal Ablation Remits Primary Aldosteronism: A Randomized Medication-Controlled Trial.
作者: Zhigang Zhao.;Xiaoli Liu.;Hexuan Zhang.;Qiang Li.;Hongbo He.;Zhencheng Yan.;Fang Sun.;Yingsha Li.;Xunmei Zhou.;Xiaona Bu.;Hao Wu.;Rufei Shen.;Hongting Zheng.;Gangyi Yang.;Zhiming Zhu.; .
来源: Circulation. 2021年144卷7期580-582页 436. Susceptibility Locus for Pregnancy-Associated Spontaneous Coronary Artery Dissection.
作者: Tamiel N Turley.;Matthew L Kosel.;William R Bamlet.;Rajiv Gulati.;Sharonne N Hayes.;Marysia S Tweet.;Timothy M Olson.
来源: Circ Genom Precis Med. 2021年14卷4期e003398页 437. Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial.
作者: E Sebastian Debus.;Mark R Nehler.;Nicholas Govsyeyev.;Rupert M Bauersachs.;Sonia S Anand.;Manesh R Patel.;Fabrizio Fanelli.;Warren H Capell.;Taylor Brackin.;Franz Hinterreiter.;Dainis Krievins.;Patrice Nault.;Gabriele Piffaretti.;Alexei Svetlikov.;Nicole Jaeger.;Connie N Hess.;Henrik H Sillesen.;Michael Conte.;Joseph Mills.;Eva Muehlhofer.;Lloyd P Haskell.;Scott D Berkowitz.;William R Hiatt.;Marc P Bonaca.
来源: Circulation. 2021年144卷14期1104-1116页
Patients with peripheral artery disease requiring lower extremity revascularization (LER) are at high risk of adverse limb and cardiovascular events. The VOYAGER PAD trial (Vascular Outcomes Study of ASA [Acetylsalicylic Acid] Along With Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD) demonstrated that rivaroxaban significantly reduced this risk. The efficacy and safety of rivaroxaban has not been described in patients who underwent surgical LER.
438. Safety and Effectiveness of the SVELTE Fixed-Wire and Rapid Exchange Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions: Results of the OPTIMIZE Randomized Study.
作者: Dean J Kereiakes.;Robert L Feldman.;A J J Ijsselmuiden.;Shigeru Saito.;Giovanni Amoroso.;James P Zidar.;S Chiu Wong.;Pieter Stella.;Steven Yakubov.;John Lasala.;David J Cohen.;Gheorghe Doros.;Donald E Cutlip.;Sunil V Rao.
来源: Circ Cardiovasc Interv. 2021年14卷9期e010609页
[Figure: see text].
439. Placebo-Controlled Efficacy of Percutaneous Coronary Intervention for Focal and Diffuse Patterns of Stable Coronary Artery Disease.
作者: Christopher A Rajkumar.;Matthew Shun-Shin.;Henry Seligman.;Yousif Ahmad.;Takayuki Warisawa.;Christopher M Cook.;James P Howard.;Sashiananthan Ganesananthan.;Laura Amarin.;Caitlin Khan.;Ayesha Ahmed.;Alexandra Nowbar.;Michael Foley.;Ravi Assomull.;Niall G Keenan.;Joban Sehmi.;Thomas R Keeble.;John R Davies.;Kare H Tang.;Robert Gerber.;Graham Cole.;Peter O'Kane.;Andrew S P Sharp.;Ramzi Khamis.;Gajen Kanaganayagam.;Ricardo Petraco.;Neil Ruparelia.;Iqbal S Malik.;Sukhjinder Nijjer.;Sayan Sen.;Darrel P Francis.;Rasha Al-Lamee.
来源: Circ Cardiovasc Interv. 2021年14卷8期e009891页
[Figure: see text].
440. Clinical Genetic Risk Variants Inform a Functional Protein Interaction Network for Tetralogy of Fallot.
作者: Miriam S Reuter.;Rajiv R Chaturvedi.;Rebekah K Jobling.;Giovanna Pellecchia.;Omar Hamdan.;Wilson W L Sung.;Thomas Nalpathamkalam.;Pratyusha Attaluri.;Candice K Silversides.;Rachel M Wald.;Christian R Marshall.;Simon G Williams.;Bernard D Keavney.;Bhooma Thiruvahindrapuram.;Stephen W Scherer.;Anne S Bassett.
来源: Circ Genom Precis Med. 2021年14卷4期e003410页
Tetralogy of Fallot (TOF)-the most common cyanotic heart defect in newborns-has evidence of multiple genetic contributing factors. Identifying variants that are clinically relevant is essential to understand patient-specific disease susceptibility and outcomes and could contribute to delineating pathomechanisms.
|